Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-α2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trial

Robert A. Ogert, John A. Howe, John M. Vierling, Paul Y. Kwo, Eric J. Lawitz, Jonathan McCone, Eugene R. Schiff, David Pound, Mitchell N. Davis, Stuart C. Gordon, Natarajan Ravendhran, Lorenzo Rossaro, Ira M. Jacobson, Robert Ralston, Eirum Chaudhri, Ping Qiu, Lisa D. Pedicone, Clifford A. Brass, Janice K. Albrecht, Richard J O BarnardDaria J. Hazuda, Anita Y M Howe

Research output: Contribution to journalArticlepeer-review

16 Scopus citations

Fingerprint Dive into the research topics of 'Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-α2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences